Effects of valsartan treatment on indicators of cardiovascular damage in newly diagnosed hypertensive patients: A prospective, twelve-month, open-label, pilot study  by Carugo, Stefano et al.
CURRENT THERAPEUTIC RESEARCH
VOI.UM E 7 1, N UMliER 5 . O CrOE\ER 20 10
Effects of Valsartan Treatment on Indicators of
Cardiovascular Damage in Newly Diagnosed
Hypertensive Patients: A Prospective, Twelve-Month,
Open-Label, Pilot Study
Stefano Carugo , MDI; Gian Battista Bolla, M02 ; Roberta Parniani, B51;
Barbara Caimi , MD2; Giuseppe Rossetti, MDI; Francesco Brasca, MDI;
and Fabio Magrin i, MD 2
]Department ofCardiac Rehabilitation A SP IMMeS and Pia Albergo Trivu/zio, University
of Milan, Milan, Italy; and 2Thoracic, Pulmonary and Cardiocirculatory Department,
University ofMilan, Milan, Italy
ABSTRACT
BACKGROUND: Myocard ial fibrosis and dysfunction can be detected in the early
phases of organ damage associated with hypertension. Valsartan, an angiorensin-Il recep-
tor blocker, is efficacious in lowering blood pressure (BP) and reducing left ventricular
mass in patients with hypertension. Levels of N-terminal pro-brain natriuretic pept ide
(NT-p roBN P) and proco llagen eype I carboxy-terminal propeptide (PICP) are corre-
lated wi th organ damage in pat ient s wi th overt congestive heart failure; however, few
data are available in pat ients with hypertension.
OBJECTIVE: The aim of th is study was to assess the effects of 12 months of valsarran
treatment on echocardiographic measures and indices of organ damage (NT-proBN P
and PICP) in newly diagnosed patients with hypertension.
METHODS: This was a prospective, open-label, single-center, exploratory study.
Patients with newly diagnosed , previously untreated hypertension were treat ed for
12 months with valsarran 160 mg/d and compared with an equal number of health y,
untreated cont rol subjects. Baseline and follow-up visits at 3, 6, and 12 months included
physical examination , systolic BP (SBP) and diastol ic BP (DBP) measurements, ECG ,
echocard iography, and NT- proBNP and PICP determ ination.
RESULTS: A total of20 patients (mean [SD} age, 48.05 [7.29} years) were enrolled
and compared with 20 health y cont rols (age, 49.6 [6.95} years). Compared with base-
line, valsartan was associated with reduced BP in the gro up with hypertension after
12 months of treatment (mean SBP, 150.05 [ll.l 5} vs 120.00 [S.43} mm Hg,
P < 0.00 1; DBP, 97.80 [8.36} vs 79.50 [4.26} mm Hg, P < 0.00 1). Compared with the
cont rol g roup, at baseline, the group with hypertension had sig nificant ly high er mean
left ventricu lar mass index (l VMI) (119.88 [22.86J vs 87.3 1 [l 5.77} g/m 2; P < 0.00 1),
relati ve wall th ickness (thickness/radius [hfr] ratio: 0.45 [O.OS} vs 0.35 [0.07]; P =
0.001), and NT-proBNP (50.00 {32 .01 ) vs 25 .4 7 [9 .69) pg/dL ; P = 0.0 02). PICP
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was higher, but the difference was not statistically significant (46.10 [15.69] vs
37.50 [7.20] pglL). After 12 months, treatment with valsartan was associated with signif-
icant reductions in all measured parameters compared with baseline (LVMI, 106.51
[17.12] g/m2 , P = 0.004; h/r, OA1 (O.On P = 0.026; NT-proBNP, 22.55 [13.52] pg/dL,
P = 0.001; PICP, 35.20 [9.19] pglL, P < 0.008). At 12 months, patients with hyperten-
sion treated with valsartan achieved NT-proBNP and PICP levels not statistically different
from those of the healthy controls (NT-proBNP, 22.55 {l3.52] vs 25.24 (8A3] pg/dL;
PICP, 35.20 [9.19] vs 36.90 {6Al} pg/L).
CONCLUSION: Patients treated with valsartan for 12 months had significant
reductions in BP, LVMI, and indices of subclinical organ damage (NT-proBNP and
PICP) compared with baseline. (Curr Ther Res Clin Exp. 2010;71:309-321) © 2010
Elsevier HS ] ournals, Inc.
KEY WORDS: hypertension, organ damage, ang iotensin-Il receptor blocker,
valsartan, N-terminal pro-brain natriuretic peptide, procollagen type I carboxy-terminal
propeptide.
INTRODUCTION
Hypertension is a major cardiovascular (CV) risk factor, and essential hypertension
is considered an early stage in the continuum of CV disease, which progresses from
atherosclerosis to fatal or nonfatal events. 1 Long-standing hypertension is associated
with well-known modifications in heart structure and function, commonly repre-
sented by left ventricular hypertrophy (LVH) and left ventricular systolic and diastolic
dysfunction (LVSDd). Echocardiography is deemed the gold standard for the detection
of LVSDd preceding overt heart failure. 2,3
The natriuretic peptide (NP) family plays a key role in blood pressure (BP) regula-
tion through its direct vasodilator, diuretic, and natriuretic properties.f The NP fam-
ily includes atrial NP (ANP) and brain NP (BNP), as well as the N-terminal (NT)
fragments of their biosynrhetic precursors (NT-proANP and NT-proBNP). BNP and
NT-proBNP have been identified as simple tools to facilitate identification of LVH
and LVSDd. 5 Plasma concentrations of cardiac-derived NPs have been associated with
cardiac function and are considered hallmarks of congestive heart failure.? BNP, in
particular, is a sensitive and very early indicator of ventricular wall stress," and studies
have suggested that the N-terminal fragment of the molecule is "at least equivalent"
to BNP for the detecrion of LVSDd.7,8
There is increasing evidence that subclinical target organ damage occurs also in the
early phases of the natural history of hypertension.9-11 One common early event in the
development of heart damage associated with hypertension is LVH, which can result
from myocyte hypertrophy and interstitial accumulation of fibrous tissue.V
In patients with hypertension, myocardial fibrosis has a direct negative effect on
clinical outcomes, because a higher collagen content increases myocardial stiffness,
promotes cardiac dysfunction, and induces abnormalities of electrical activity and
intramyocardial perfusion.l ' This suggests that the quantity and quality of cardiac
tissue are responsible for CV events in these patients.I" During the synthesis of collagen
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type 1, procollagen type I carboxy-terminal propeptide (PICP) is formed and released
into the blood, and high serum concentrations ofPICP can be found in cardiac fibrosis. 15
Therefore, serum levels of PICP have been proposed as a good marker of collagen type I
synthesis and severe myocardial fibrosis. 16 ,17 In fact, circularing biomarkers of colla-
gen turnover are currently known to provide a useful tool for the assessment of cardiac
remodeling in patients with congestive heart failure and LVSDd after acute myocar-
dial infarction. 18 Moreover, it has been found that serum PICP is higher in any setting
of hypertensive heart disease than in normotensive controls.
Lowering BP is critical to reducing the CV complications of hypertension!"; how-
ever, hemodynamic and nonhemodynamic factors play synergistic roles in myocardial
fibrosis.I"
Chronic pressure overload stimulates excessive collagen deposition. However, other
biological variables may contribute to this process because the ability of antihypertensive
treatment to reduce BP does not predict the extent of myocardial fibrosis regression."
Therefore, it seems reasonable that optimal treatment of arterial hypertension might
favor the decrease of both cardiac mass and fibrosis. Preliminary evidence suggests
that not all antihypertensive agents affect fibrosis to the same extent. Drugs that di-
rectly block the renin-angiotensin system (angiotensin-converting enzyme [ACE}
inhibitors and angiotensin II receptor blockers [ARBs}) appear to be particularly ef-
ficacious in contrast to l3-blockers and diuretics.? ARBs have been found to be as ef-
ficacious as ACE inhibitors in the management of hypertension, congestive heart
failure, and chronic renal failure. 22 Several studies have reported that the ARB vaisar-
tan is nor only an efficacious antihypertensive drug, bur also is able to reduce left
ventricular mass (LVM) and myocardial dysfunction and fibrosis. 22.2J
The present study was conducted to assess the effects of treatment with valsar-
tan on both echocardiography parameters and circulating indices of heart damage (ie,
NT-proBNP and PICP), in a population with newly diagnosed, previously untreated
hypertension.
SUBJECTS AND METHODS
The study was approved by the local ethical committee at the University of Milan,
Milan, Italy. All subjects were adequately informed of the nature of this clinical trial,
and gave written informed consent prior to their participation. The study was conduered
in accordance with the second amendment to the Declaration of Helsinki.
PARTICIPAI'o1TS AND PROCEDURES
A 12-month, open-label, single-center, exploratory study was conduered on men
and women aged ~ 18 years. Consecutive, nonselected patients with newly diagnosed,
previously untreated arterial hypertension, who were referred to the authors' clinic for
evaluarion and treatment of the disease, were included in the hypertension group.
Hypertension was defined by repeatedly documented systolic BP (SBP) > 139 mm Hg
and diastolic BP (DBP) >89 mm Hg. The presence of a hypertensive condition sec-
ondary to renal disorders, renal artery abnormalities, adrenocortical disorders, pheo-
chrornocyrorna, and iatrogenic causes was systematically excluded by analysis of blood
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samples and clinical evaluations, and echography of the upper abdomen in suspected
nephrovascular hypertension. Patients in the hypertensive group received valsarran
160 mg/d orally in the morning, during the entire 12-momh study period. Valsarran
had to have been their first antihypertensive treatment, and concomitant antihyper-
tensive medications were not allowed during the observation period.
The control group included healthy, normotensive, adult subjects of both sexes who
had been referred to the center and determined to be normal. Healthy volunteers were
recruited from the volunteer database at the center and evaluated in the same manner.
This group received no antihypertensive treatment.
Study visits were performed at baseline and then at 3, 6, and 12 months. At each
visit, every participant underwent a complete physical examination, BP measurement,
venous blood sample collection, ECG, and echocardiographic examination. SBP and
DBP were measured in the sitting position after 5 minutes of rest, using a conventional
sphygmomanometer with an appropriately sized cuff on the left upper arm. After over-
night fasting, venous blood samples were drawn for both routine laboratory tests
(including glucose, creatinine, and urea nitrogen), and determination of NT-proBNP
and PICP. Blood samples for the measurement of plasma NT-proBNP and PICP con-
centrations were collected in 7-mL disodium-EDTA-containing test tubes, and imme-
diately centrifuged at 3000 rpm for 10 minutes. Plasma samples from each patient
were stored in 2 separate I-mL vials until they were analyzed by an investigator (G.B.B.)
who was blinded to the study group designation. Plasma levels of NT-proBNP were
measured by an electrochemiluminescent immunoassay (Elecsys, Roche Diagnostics,
Mannheim, Germany), whereas PICP levels were determined by a commercially available
radioimmunoassay (Procollagen PICP RIA Kit, Orion Diagnostics, Espoo, Finland)
Two-dimensional echocardiography and targeted M-mode recording were obtained
in each patient as recommended. Echocardiography was performed (Sonoline G50,
Siemens AG, Erlangen, Germany) with a 2.5- or 3.5-MHz probe. Images were ob-
rained from the parasternal and apical windows, with the patient lying on his Or her
left side. All of the recordings were performed at the end of expiration, to get the best
quality images. LVM was calculated by the Devereux formula/":
LVM = 1.04 X [(LVIDd + IVSd + PWTd)3 - LVIDd3] - 13.6,
where LVIDd was the left ventricular end-diastolic internal diameter, IVSd was the
end-diastolic interventricular septum thickness, and PWTd was the left ventricular
end-diastolic posterior wall thickness. LVM index (LVMl) was calculated by dividing
the LVM by body surface area. Left ventricular thickness/radius (hit) ratio was calcu-
lated by dividing the sum of IVSd and PWTd by LVIDd (normal value <0.45). All
measurements were carried out by an echocardiographer (B.C. or G.R.) blinded to
treatment groups.
STATISTICAL ANALYSIS
Continuous variables (SBP, DBP, LVMI, hlr, NT-proBNP, and PICP) were ex-
pressed in terms of mean (SD). Comparisons between groups for BP and biomarker
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values were performed by t test for independent groups. In each group, changes from
baseline to 12 months in BP values and biomarker concentrations were analyzed by
paired t test. ProBNP and PICP values usually have a skewed distribution; therefore,
they were log-transformed before t test analyses. Oifferences in gender distribution
between the hypertension and control groups were assessed by Fisher exact test. The
level of significance was fixed at 0.05 for 2-sided tests. The Bonferroni correction was
adopted to assess significance in multiple comparisons. According to this criterion, to
maintain the family-wise error rate (that is, the significance level for the whole family
of tests) at 0.05, each of the individual k tests carried out on each parameter was
judged significant if the observed P value was <0.05/k.
All statistical analyses were performed using SAS software version 8.2 (SAS Institute
Inc., Cary, North Carolina).
RESULTS
Thirty-five hypertensive patients were approached for enrollment, 15 of whom were ex-
cluded from the study (8 for secondary hypertension, 5 for refusal of consent, and 2 for
having "white coat" hypertension). Therefore, the study population included 20 patients
in the hypertension group (7 females and 13 males; mean [SO} age, 48.05 [7.29} years
[range, 36--62 years}) and 20 controls (10 females and 10 males; age, 49.6 [6.95} years
[range, 38-58 years}). Data were available from all 40 enrolled subjects; all participants in
both groups completed the study and were included in the effectiveness analysis. Hyper-
tension and healthy control groups were not significantly different in terms of age or sex.
BLOOD PRESSURE CONTROL
At baseline, mean (SO) SBP was 150.05 (11.15) mm Hg and OBP was 97.80
(8.36) mm Hg in the hypertension group, compared with 116.50 (10.27) mm Hg and
79.50 (4.84) mm Hg, respectively, in the control group. The difference between the
hypertension group and the control group was statistically significant for both SBP
and OBP (both, P < 0.001).
Treatment with valsartan 160 mg/d was associated with reduced BP values in patients
with hypertension, allowing them to reach recommended therapeutic goals (Figure 1).
After 12 months of treatment, mean (SO) SBP and OBP values in the hypertension
group were 120.00 (8.43) mm Hg and 79.50 (4.26) mm Hg, respectively (both, P <
0.001 vs baseline). There were no significant differences between BP measurements at
baseline and those at 12 months in the control group.
ECHOCARDIOGRAPHIC PARAMETERS
Figure 2 shows LVMI and h/r values at baseline and 12 months in both study
groups. At baseline, mean (SO) LVMI was significantly higher in hypertensive pa-
tients (119.88 [22.86} g/rn-') compared with healthy controls (87.31 [15.77} g/m2 ;
P < 0.001). Similarly, the h/r ratio was significantly higher in the hypertensive group
(0.45 [0.08}) compared with the control group (0.35 [0.07}; P < 0.001).
In the hypertensive group, after 12 months of treatment with valsartan, mean (SO)
LVMI was significantly improved compared with baseline (106.51 [17 .12} g/rn"; change
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Figure 1. Mean (SD) systolic blood pressure (SSP) and diastolic SP (DSP) in the hyper-
tensive group (at baseline and at 3, 6, and 12 months of valsartan treatment)
and in the healthy control group (at baseline and at 12 months).
from baseline, -13.17 {20.441; P = 0.004). Values for h/r ratio at 12 months showed
an improvement compared with baseline (0.41 {O.O]]; change from baseline, -0.04
{0.08}; P = 0.026), although the difference lacked statistical significance according to
the Bonferroni correction. The results at 12 months in the control group were virtu-
ally unchanged compared with baseline (LVMI baseline, 87.31 [15.77} g/rn? vs
12 months, 82.96 {l8.88} g/rn"; h/r baseline, 0.35 {o.on vs 12 months, 0.34 {0.08}).
Between-group differences in LVMI and hit values at 12 months were lower compared
with baseline, but still remained significant after 12 months (P < 0.001 for LVMI and
P < 0.005 for h/r).
MARKERS OF ORGAN DAMAGE
Figure 3 shows the NT-proBNP and PICP values at baseline and 12 months in
both study groups. At baseline, mean (SO) NT-proBNP levels were significantly
higher in hypertensive patients (50.00 {32.0l} pg/dL) compared with healthy controls
(25.47 {9.69} pg/dL; P = 0.002 after log-transformation). PICP levels were numeri-
cally higher in the hypertension group (46.10 {l5.69} j.1g/L) compared with the con-
trol group (37.50 {7.20} pg/L), but this difference was not statistically significant.
In the hypertension group, after 12 months of treatment with valsartan, mean (SD)
NT-proBNP levels significantly improved compared with baseline (22.55 [13.5 2} pgl
dL; change from baseline, -27.45 {30.88} pg/dL; P < 0.002 after log-transformation).
PICP levels were also significantly lower compared with baseline (35.20 {9.19} j.1g/L;
change from baseline, -10.90 {l4.31} j.1g/L; P < 0.008 after log-transformation). Simi-
larly to LVMI and h/r ratios, the results at 12 months for NT-proBNP and PICP in
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Figure 2. Mean (SO) (A) left ventricular mass index (LVMI) and (B) left ventricular thicknessl
radius (h/r) ratio values at baseline and at 12 months in the hypertensive and
healthy control groups. *p < 0.001 versus the control group; tp =0.001 versus
the control group; 'l'p =0.004 versus baseline; §p < 0.005 versus the control
group; lip =0.026 versus baseline.
the control group were virtually unchanged compared with baseline (NT-proBNP
baseline, 25.47 [9.69} pg/dL vs 12 months, 25.24 [8.43} pg/dL; PICP baseline,
37.50 p.20} I1g/L vs 12 months, 36.90 [6.41] I1g/L). Therefore, after 12 months of
valsartan treatment, NT-proBNP and PICP levels in patients with hypertension were
not statistically different from those of healthy controls.
DISCUSSION
Twelve months of monotherapy with valsartan 160 mg/d was associated with signifi-
cantly reduced BP values to recommended targets « 140/90 mm Hg) in all patients
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Figure 3. Mean (SD) (A) N-terminal pro-brain natriuretic peptide (NT-proBNP) and (B) pro-
collagen type I carboxy-terminal propeptide (PICP) values at baseline and at
1.2 months in the hypertensive and healthy control groups. *P = 0.002 versus
the control group; tp = 0.002 versus baseline; fP < 0.008 versus baseline.
with newly diagnosed, previously untreated hypertension enrolled in the present study.
This finding is consistent with the results of several large studies on valsartan, such as
the VALUE trial 25 and the recent PREVIEW study.26 The Canadian Valsartan Obser-
vational Study (DIOVANTAGE 4)27 included 34,033 patients with essential hyper-
tension treated with valsartan (alone or in combination with hydrochlorothiazide),
38% of whom were newly diagnosed with hypertension. This trial confirmed the
benefits of single-drug treatment with valsartan 80 or 160 mg/d for controlling BP,
along with good safety and tolerability profiles. Furthermore, monotherapy with an
ARB such as valsartan is among the regimens recommended by European guidelines
to adequately lower BP and improve cardiovascular outcomes.P'
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In the present study, the satisfactory BP control obtained during the entire follow-
up period is in accordance with the significant improvements observed in echocardio-
graphic parameters, although both LVMI and hit ratios remained higher in hyperten-
sive subjects than in normotensive subjects after 12 months. This finding may be
related to the time lag between the onset of successful antihypertensive treatment and
achievement of full regression of these morphologic changes. On the contrary, hyper-
tensive patients had significantly higher NT-proBNP and PICP values at baseline
compared with the healthy controls, and these differences were not statistically signifi-
cant at study end point. Although the results come from a small group of patients, the
reliability of these findings is supported by the stability of both indices after 12 months
in normotensive subjects lacking other causes of heart damage. And, although both
baseline NT-proBNP and PICP concentrations in the hypertensive group were within
the reported normal ranges 13,29 for subjects with normal heart function, there were
significant decreases in their values after 12 months of valsartan treatment, consistent
with regression of subclinical organ damage.
The data presented here, in accordance with those in the literature, suggest a po-
tential beneficial action of valsartan beyond JUSt the reduction of BP, in the early phase
of hypertensive disease. 3D In fact, the early changes in organ damage markers should
not---or at least should not completely-be ascribed to the extent of BP reduction.
Evidence from experimental models indicates that not all antihypertensive agents
have antifibroric effects and cardiovascular tissue specificity.t! In small studies based
on cardiac biopsies in humans, treatment with different antihypertensive drugs was
associated with varying degrees of myocardial fibrosis regression. Furthermore, it was
reported that the ability of antihypertensive treatment to reduce BP did not predict
its capacity to reverse myocardial fibrosis.!"
Agents directly blocking the renin-angiotensin system appear to be particularly
active in promoting regression of fibrosis, in contrast to f)-blockers and diuretics. In
fact, angiotensin II induces vasoconstriction, cell proliferation, and collagen synthesis,
contributing to the development of hypertrophy, myocardial fibrosis, and cardiac re-
modelling.V A large body of evidence supports a major role for angiotensin II as a
critical factor responsible for both fibroblast proliferation and alteration of fibrillar
collagen turnover, which in turn lead to increased myocardial stiffness and promote
diastolic and systolic dysfunction, electrical activity abnormalities, and impaired in-
tramyocardial perfusion. l3 In this context, the ACE-inhibitor lisinopril was associated
with significantly less cardiac fibrosis than hydrochlorothiazide in a small series of
hypertensive patients enrolled in a double-blind, randomized trial,33 In the LVH Re-
gression with the Angiotensin Antagonist Losartan (REGAAL) study, which included
225 patients, the ARB losartan reduced both LVMI and BNP compared with the
f)-blocker atenolol. 34 Moreover, losartan, bur not the calcium channel blocker amlo-
dipine, was associated with a decrease in collagen volume fraction and PICP values in
hypertensive patients.P leading the authors to suggest that PICP levels might be used
to determine treatment effectiveness on myocardial fibrosis. Diez et aP6 also found that
losartan treatment was associated with a decrease in PICP levels, but only in patients
with severe myocardial fibrosis. 16
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In the present study, pat ients with newly diagnosed arterial hypertension and sub-
clinical organ damage were treated with valsart an for 12 months, showing a favorabl e
effect of the drug in thi s populat ion . The findings are consi stent with data from the
large Valsartan Heart Failure Trial ,37 in which baseline BNP values were recorded in
4284 patients with symptomaric chronic heart failure randomly assigned to valsartan
or placebo as add-on to standard treatment. In the valsarran group, plasma BNP levels
showed a significant reduction after 4, 12, and 24 months of follow-up. In the placebo
group, plasma BNP concentrations progressively increased (P < 0.001 in all compari-
sons vs placebo, at each time point). Furthermore, the benefit of valsartan on BNP
levels in thar trial was also observed in patients already treated with an ACE inhibitor
and a l3-blocker, and was consistent with an improvement of left ventricular function,
although this latter observation did not affect mortality rates.
Ir should be noted that this study was not designed to investigate whether valsarran
is more efficacious than diuretics or l3-blockers in reducing the outcomes measured.
As of the writing of this art icle, there is no study in the literature indicating that
l3-blockers or diuretics reduce PICP, because these drugs, in effect, lack any direct action
on collagen and procollagen. Therefore, while this analysis cannor definitively suggest
th at the outcomes were due to valsartan in particular, and althoug h it is possible that
the results came from BP reduction alone , it seems that valsartan exerted a major
effect on the measured parameters. BP control may be an additional favorable facto r
especially regarding the BNP decrease; however, the effect of ARBs on PICP is evident.
A study including a control group receiving a different antihypertensive treatment
might help to clarify this point.
Limitations of the present study include its small sample size, though it was in-
tended to be exploratory in nature. For this reason, it was not possible to analyze the
severity of hypertension at baseline, or correlate it with circulat ing indices of subclini-
cal organ damage or with the effects of I-year valsartan ad ministrat ion on their levels .
However, rhe between-group differences in NT-proBNP and PICP concentrations at
baseline were clearly evident, as was their disappearance after 1 year of treatment.
While levels of NT-proBNP are known to be higher in women than in men, 38 and
this study enrolled 10 women and 10 men in the control group compared with 7 women
and 13 men in the hypertension group, higher levels of this marker were found in the
patients with hypertension than in the control group at baseline. There was no statis-
tical difference between groups after 12 months of follow-up. In addition, the results
were supported by the coherence of changes in NT-proBNP and PICP over time, as
the patients of this study were not affected by other conditions known to be associated
with altered PICP, such as renal impairment, coronary artery disease, hepatic dysfunc-
tion , pulmonary fibrosis, or metabolic bone disease.
The clinical relevance of these findings stems from recommendations in the guide-
lines from the European Societ y of Hypertension.P' underscoring the importance of
preventing organ dam age due to hypertension in an early phase of the disease. Valsar-
tan is the first drug found to have effects on such an important marker as PICE In this
perspective, it is also important to note that mortality has not been shown to be dif-
ferent with the use of valsarran over other drugs.
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CONCLUSIONS
In th is stu dy, pati ents treated with valsartan for 12 months had sig nificant redu ct ions
in BP, LVMI , and ind ices of subclinical organ damage (NT-p roBN P and PICP) com-
pared with baseline. Furtherm ore, th e sig nificant decrease of N T-proBN P and PICP,
indices of early heart dysfunct ion and fibrosis, sugges ts that furt her investigations are
warrant ed to evalu ate th e potent ial effeers of valsartan on th e prevention or delay of
target organ damage.
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